Coherus BioSciences (CHRS) Misses Q2 EPS by 8c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.34 +16.52%
Financial Fact:
Total operating expenses: 234.36M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Total operating expenses: 234.36M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.34), $0.08 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $10.25 million versus the consensus estimate of $10.16 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cinema United: issues joint letter to state AGs and Paramount
- Prenetics Global (PRE) Tops Q2 EPS by 18c
- Boeing-Lockheed space venture inks $1.5 billion private bonds - Bloomberg
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
